search
Back to results

A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Oral semaglutide
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy, female subjects who have given birth at least 3 months prior to screening and who breastfeed (breastfeeding is defined by feeding the baby milk produced by the mother. Using a breast pump to collect milk and subsequently feeding it to the baby by bottle, is also defined as breastfeeding ) their infant to an extent, where the majority of the infant's total energy intake is from breastfeeding and sufficient milk is produced to fulfil the trial requirements, as judged by the investigator.
  • Agree to abstain from breastfeeding their infant from first dose of oral semaglutide to the "End of trial" visit (total of 47 days) to avoid potentially exposing their child to semaglutide and SNAC.
  • The breastfed infant is able to feed from a bottle (expenses related to alternative infant nutrition during trial participation will be covered by Novo Nordisk) prior to screening.
  • Age above or equal to 18 years at the time of agreement to take part.
  • Body mass index (BMI) between 20.0 and 32.4 kg/m^2 (both inclusive).

Exclusion Criteria:

  • Female who is pregnant or intends to become pregnant or is of child-bearing potential and not using an effective contraceptive method.
  • Glycated haemoglobin (HbA1c) greater than or equal to 6.5 % (48 mmol/mol) at screening.
  • Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator.
  • History (as declared by the subject or reported in the medical records) of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).
  • Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (as declared by the subject or reported in the medical records).
  • Presence or history (as declared by the subject or reported in the medical records) of malignant neoplasm within 5 years prior to the day of screening (basal or squamous cell skin cancer, or any carcinoma in-situ is allowed).
  • Presence or history (as declared by the subject or reported in the medical records) of pancreatitis (acute or chronic).

Sites / Locations

  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Oral semaglutide

Arm Description

All participants will receive oral semaglutide once daily for a total of 10 days: 3 mg for 5 days followed by 7 mg for 5 days.

Outcomes

Primary Outcome Measures

Area under the semaglutide milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,milk)
nmol*h/L
Area under the salcaprozate sodium (SNAC) milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,milk)
ng*h/mL

Secondary Outcome Measures

Average semaglutide milk concentration during a dosing interval after the 10th dosing (Cavg,sema,D10,milk)
nmol/L
Maximum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,milk)
nmol/L
Minimum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmin,sema,D10,milk)
nmol/L
Time to maximum semaglutide milk concentration during a dosing interval after the 10th dosing (tmax,sema,D10,milk)
Hours
Estimated daily infant semaglutide dose
mg/kg/day
Relative daily infant semaglutide dose
Average SNAC milk concentration during a dosing interval after the 10th dosing (Cavg,SNAC,D10,milk)
ng/mL
Maximum SNAC milk concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,milk)
ng/mL
Minimum SNAC milk concentration during a dosing interval after the 10th dosing (Cmin,SNAC,D10,milk)
ng/mL
Time to maximum SNAC milk concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,milk)
hours
Estimated daily infant SNAC dose
ng/kg/day
Relative daily infant SNAC dose
Area under the SNAC metabolite E494 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,milk)
ng*h/mL
Average SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cavg,E494,D10,milk)
ng/mL
Maximum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,milk)
ng/mL
Minimum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmin,E494,D10,milk)
ng/mL
Time to maximum SNAC metabolite E494 milk concentration after the 10th dosing (tmax,E494,D10,milk)
hours
Estimated daily infant SNAC metabolite E494 dose
ng/kg/day
Area under the SNAC metabolite E506 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,milk)
ng*h/mL
Average SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cavg,E506,D10,milk)
ng/mL
Maximum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,milk)
ng/mL
Minimum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmin,E506,D10,milk)
ng/mL
Time to maximum SNAC metabolite E506 milk concentration after the 10th dosing (tmax,E506,D10,milk)
hours
Estimated daily infant SNAC metabolite E506 dose
ng/kg/day
Area under the SNAC metabolite E1245 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,milk)
ng*h/mL
Average SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cavg,E1245,D10,milk)
ng/mL
Maximum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,milk)
ng/mL
Minimum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmin,E1245,D10,milk)
ng/mL
Time to maximum SNAC metabolite E1245 milk concentration after the 10th dosing (tmax,E1245,D10,milk)
hours
Estimated daily infant SNAC metabolite E1245 dose
ng/kg/day
Area under the SNAC metabolite E1246 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,milk)
ng*h/mL
Average SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cavg,E1246,D10,milk)
ng/mL
Maximum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,milk)
ng/mL
Minimum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmin,E1246,D10,milk)
ng/mL
Time to maximum SNAC metabolite E1246 milk concentration in milk after the 10th dosing (tmax,E1246,D10,milk)
hours
Estimated daily infant SNAC metabolite E1246 dose
ng/kg/day
Area under the SNAC metabolite E1247 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,milk)
ng*h/mL
Average SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cavg,E1247,D10,milk)
ng/mL
Maximum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,milk)
ng/mL
Minimum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmin,E1247,D10,milk)
ng/mL
Time to maximum SNAC metabolite E1247 milk concentration after the 10th dosing (tmax,E1247,D10,milk)
hours
Estimated daily infant SNAC metabolite E1247 dose
ng/kg/day
Area under the semaglutide plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,plasma)
nmol*h/L
Maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,plasma)
nmol/L
Time to maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (tmax,sema,D10,plasma)
hours
Area under the SNAC plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,plasma)
ng*h/mL
Maximum SNAC plasma concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,plasma)
ng/mL
Time to maximum SNAC plasma concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,plasma)
hours
Area under the SNAC metabolite E494 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,plasma)
ng*h/mL
Maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,plasma)
ng/mL
Time to maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (tmax,E494,D10,plasma)
hours
Area under the SNAC metabolite E506 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,plasma)
ng*h/mL
Maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,plasma)
ng/mL
Time to maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (tmax,E506,D10,plasma)
hours
Area under the SNAC metabolite E1245 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,plasma)
ng*h/mL
Maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,plasma)
ng/mL
Time to maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (tmax,E1245,D10,plasma)
hours
Area under the SNAC metabolite E1246 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,plasma)
ng*h/mL
Maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,plasma)
ng/mL
Time to maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (tmax,E1246,D10,plasma)
hours
Area under the SNAC metabolite E1247 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,plasma)
ng*h/mL
Maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,plasma)
ng/mL
Time to maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (tmax,E1247,D10,plasma)
hours

Full Information

First Posted
March 23, 2021
Last Updated
July 7, 2023
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT04817644
Brief Title
A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets
Official Title
A Trial Investigating Semaglutide and SNAC Concentrations in Breastmilk Following Administration of Multiple Doses of Oral Semaglutide in Healthy, Lactating Females
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
September 10, 2021 (Actual)
Primary Completion Date
May 26, 2023 (Actual)
Study Completion Date
July 3, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Participants in the study, will receive the study drug once daily for 10 days in tablet form for oral (by mouth) intake. On day 1 to 5 the tablet will contain 3 mg semaglutide, and on day 6-10 the tablet will contain 7 mg semaglutide.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
14 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Oral semaglutide
Arm Type
Experimental
Arm Description
All participants will receive oral semaglutide once daily for a total of 10 days: 3 mg for 5 days followed by 7 mg for 5 days.
Intervention Type
Drug
Intervention Name(s)
Oral semaglutide
Intervention Description
Oral semaglutide once daily for a total of 10 days
Primary Outcome Measure Information:
Title
Area under the semaglutide milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,milk)
Description
nmol*h/L
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Area under the salcaprozate sodium (SNAC) milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,milk)
Description
ng*h/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Secondary Outcome Measure Information:
Title
Average semaglutide milk concentration during a dosing interval after the 10th dosing (Cavg,sema,D10,milk)
Description
nmol/L
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,milk)
Description
nmol/L
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Minimum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmin,sema,D10,milk)
Description
nmol/L
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum semaglutide milk concentration during a dosing interval after the 10th dosing (tmax,sema,D10,milk)
Description
Hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Estimated daily infant semaglutide dose
Description
mg/kg/day
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Relative daily infant semaglutide dose
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Average SNAC milk concentration during a dosing interval after the 10th dosing (Cavg,SNAC,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum SNAC milk concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Minimum SNAC milk concentration during a dosing interval after the 10th dosing (Cmin,SNAC,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum SNAC milk concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,milk)
Description
hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Estimated daily infant SNAC dose
Description
ng/kg/day
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Relative daily infant SNAC dose
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Area under the SNAC metabolite E494 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,milk)
Description
ng*h/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Average SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cavg,E494,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Minimum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmin,E494,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum SNAC metabolite E494 milk concentration after the 10th dosing (tmax,E494,D10,milk)
Description
hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Estimated daily infant SNAC metabolite E494 dose
Description
ng/kg/day
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Area under the SNAC metabolite E506 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,milk)
Description
ng*h/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Average SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cavg,E506,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Minimum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmin,E506,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum SNAC metabolite E506 milk concentration after the 10th dosing (tmax,E506,D10,milk)
Description
hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Estimated daily infant SNAC metabolite E506 dose
Description
ng/kg/day
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Area under the SNAC metabolite E1245 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,milk)
Description
ng*h/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Average SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cavg,E1245,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Minimum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmin,E1245,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum SNAC metabolite E1245 milk concentration after the 10th dosing (tmax,E1245,D10,milk)
Description
hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Estimated daily infant SNAC metabolite E1245 dose
Description
ng/kg/day
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Area under the SNAC metabolite E1246 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,milk)
Description
ng*h/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Average SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cavg,E1246,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Minimum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmin,E1246,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum SNAC metabolite E1246 milk concentration in milk after the 10th dosing (tmax,E1246,D10,milk)
Description
hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Estimated daily infant SNAC metabolite E1246 dose
Description
ng/kg/day
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Area under the SNAC metabolite E1247 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,milk)
Description
ng*h/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Average SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cavg,E1247,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Minimum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmin,E1247,D10,milk)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum SNAC metabolite E1247 milk concentration after the 10th dosing (tmax,E1247,D10,milk)
Description
hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Estimated daily infant SNAC metabolite E1247 dose
Description
ng/kg/day
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Area under the semaglutide plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,plasma)
Description
nmol*h/L
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,plasma)
Description
nmol/L
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (tmax,sema,D10,plasma)
Description
hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Area under the SNAC plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,plasma)
Description
ng*h/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum SNAC plasma concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,plasma)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum SNAC plasma concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,plasma)
Description
hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Area under the SNAC metabolite E494 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,plasma)
Description
ng*h/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,plasma)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (tmax,E494,D10,plasma)
Description
hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Area under the SNAC metabolite E506 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,plasma)
Description
ng*h/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,plasma)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (tmax,E506,D10,plasma)
Description
hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Area under the SNAC metabolite E1245 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,plasma)
Description
ng*h/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,plasma)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (tmax,E1245,D10,plasma)
Description
hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Area under the SNAC metabolite E1246 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,plasma)
Description
ng*h/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,plasma)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (tmax,E1246,D10,plasma)
Description
hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Area under the SNAC metabolite E1247 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,plasma)
Description
ng*h/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,plasma)
Description
ng/mL
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)
Title
Time to maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (tmax,E1247,D10,plasma)
Description
hours
Time Frame
From 0 to 24 hours after the 10th dosing (day 10)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy, female subjects who have given birth at least 3 months prior to screening and who breastfeed (breastfeeding is defined by feeding the baby milk produced by the mother. Using a breast pump to collect milk and subsequently feeding it to the baby by bottle, is also defined as breastfeeding ) their infant to an extent, where the majority of the infant's total energy intake is from breastfeeding and sufficient milk is produced to fulfil the trial requirements, as judged by the investigator. Agree to abstain from breastfeeding their infant from first dose of oral semaglutide to the "End of trial" visit (total of 47 days) to avoid potentially exposing their child to semaglutide and SNAC. The breastfed infant is able to feed from a bottle (expenses related to alternative infant nutrition during trial participation will be covered by Novo Nordisk) prior to screening. Age above or equal to 18 years at the time of agreement to take part. Body mass index (BMI) between 20.0 and 32.4 kg/m^2 (both inclusive). Exclusion Criteria: Female who is pregnant or intends to become pregnant or is of child-bearing potential and not using an effective contraceptive method. Glycated haemoglobin (HbA1c) greater than or equal to 6.5 % (48 mmol/mol) at screening. Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator. History (as declared by the subject or reported in the medical records) of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery). Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (as declared by the subject or reported in the medical records). Presence or history (as declared by the subject or reported in the medical records) of malignant neoplasm within 5 years prior to the day of screening (basal or squamous cell skin cancer, or any carcinoma in-situ is allowed). Presence or history (as declared by the subject or reported in the medical records) of pancreatitis (acute or chronic).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Transparency (dept. 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78209
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Millcreek
State/Province
Utah
ZIP/Postal Code
84124
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
IPD Sharing URL
http://novonordisk-trials.com

Learn more about this trial

A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets

We'll reach out to this number within 24 hrs